Nielka P van Erp

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 15

Top Topics

Quality Control

Prostate Cancer

Chronic Myeloid Leukemia

Renal Cell Carcinoma

Top Venues

British journal of clinical pharmacology

Clinical cancer research : an official journal of the American Association for Cancer Research

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Eline L Giraud, Stefanie D Krens, Stefan Böhringer, Ingrid M E Desar, Sita H Vermeulen, Lambertus A Kiemeney, Alwin D R Huitema, Neeltje Steeghs, Nielka P van Erp, Jesse Joachim Swen
Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer. British journal of clinical pharmacology (2024)
Dirk Jan A R Moes, Jeroen J M A Hendrikx, Henk-Jan Guchelaar, Ron H J Mathijssen, J L Bakker, Vincent O Dezentjé, Nikki de Rouw, Nielka P van Erp, Egbert F Smit, Michel van den Heuvel, Thijs H Oude Munnink, Maartje van Kats, Sander Croes, Judith R Kroep, Juliette Zwaveling, Rob Ter Heine
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan. Targeted oncology (2024)
Eva Podgoršek, Niven Mehra, Inge M van Oort, Diederik M Somford, Emmy Boerrigter, Nielka P van Erp
Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide. Clinical pharmacokinetics (2023)
Eline L Giraud, Lindsey M H Te Brake, Erik C A van den Hombergh, Ingrid M E Desar, Dina M Kweekel, Nielka P van Erp
Results of the first international quality control programme for oral targeted oncolytics. British journal of clinical pharmacology (2023)
Jeffrey Strik, Loek A W de Jong, Joost Sijm, Ingrid M E Desar, Nielka P van Erp
Effect of aprepitant on etoposide pharmacokinetics in patients with testicular cancer: a pharmacokinetic study to determine the absence of a clinically relevant interaction. Clinical pharmacology and therapeutics (2023)
Eline L Giraud, Loek A W de Jong, Erik van den Hombergh, Suzanne E J Kaal, Nielka P van Erp, Ingrid M E Desar
Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant? Cancers 15 (11) (2023)
Sofie H Tolmeijer, Emmy Boerrigter, Takayuki Sumiyoshi, Edmond M Kwan, Sarah W S Ng, Matti Annala, Grainne Donnellan, Cameron Herberts, Guillemette E Benoist, Paul Hamberg, Diederik M Somford, Inge M van Oort, Jack A Schalken, Niven Mehra, Nielka P van Erp, Alexander W Wyatt
Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Emmy Boerrigter, Guillemette E Benoist, Joanneke K Overbeek, Rogier Donders, Niven Mehra, Inge M van Oort, Rob Ter Heine, Nielka P van Erp
The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer. British journal of clinical pharmacology (2021)
Loek A W de Jong, Nielka P van Erp, Lana Bijelic
Pressurized Intraperitoneal Aerosol Chemotherapy: The Road from Promise to Proof. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (7) (2021)
Kim Westerdijk, Ingrid M E Desar, Neeltje Steeghs, Winette T A van der Graaf, Nielka P van Erp, null null
Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose. British journal of clinical pharmacology 86 (2) (2020)
Kim Westerdijk, Stefanie D Krens, Winette T A van der Graaf, Sasja F Mulder, Carla M L van Herpen, Tineke Smilde, Nielka P van Erp, Ingrid M E Desar
The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour. British journal of clinical pharmacology 87 (2) (2020)
Floor J E Lubberman, Winette T A van der Graaf, Lei Xu, Adriaan Cleton, George D Demetri, Hans Gelderblom, Nielka P van Erp
The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours. British journal of clinical pharmacology 85 (10) (2019)
Sander Zuidema, Ingrid M E Desar, Nielka P van Erp, Wietske Kievit
Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study. British journal of clinical pharmacology 85 (9) (2019)
Marie-Rose B S Crombag, Thomas P C Dorlo, Ellen van der Pan, Anoek van Straten, Andries M Bergman, Nielka P van Erp, Jos H Beijnen, Alwin D R Huitema
Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. Pharmaceutical research 36 (12) (2019)
Loek A W de Jong, Nielka P van Erp
Reply to 'Hyperthermic intraperitoneal chemotherapy with oxaliplatin-Still not standard of care for patients with colorectal peritoneal metastases' by Julianov and Saroglu. British journal of clinical pharmacology 85 (8) (2019)